Mastek Ltd
Mastek Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Mastek expects significant overall services growth driven by AI investments. - Short-term uncertainties and decision-making delays exist, but strong optimism about AI-led technology disruption remains. - North America is projected to see growth, especially in healthcare and life sciences, with improving order book to revenue conversion. - U.K. Mastek anticipates steady and positive growth in H2 FY26 despite macro and global uncertainties (Page 14).
From Mastek Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mastek expects significant overall services growth driven by AI investments.
- Short-term uncertainties and decision-making delays exist, but strong optimism about AI-led technology disruption remains.
- North America is projected to see growth, especially in healthcare and life sciences, with improving order book to revenue conversion.
- U.K. maintains a strong position with sizable multi-year renewals in secured government services and private sector growth.
- AMEA region focused on profitable growth, especially in healthcare with multi-million-dollar AI-led transformation deals.
- AI for technology drives efficiency gains allowing higher revenue per resource; AI for business expected to fuel large future transformations starting FY '27.
2 more points from Mastek Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Mastek Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Mastek is heavily investing in AI, focusing on both AI-for-technology (improving productivity and efficiency in technology services) and AI-for-business (delivering AI-led business transformation solutions).
- The company is investing in building solutions, assets, and proof of concepts in AI, with about a dozen engagements underway to build AI-for-business roadmaps for mid-market customers.
- Investments include hiring new leadership and strengthening capabilities, especially in North America, to drive growth in healthcare and life sciences.
- The firm is making targeted investments in healthcare verticals, especially in the APAC and Middle East regions.
2 more points from Mastek Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in IT - Software
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Mastek Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Mastek's 12-month order backlog as of Q2 FY'26 stood at approximately $280 million, reflecting a 2.2% sequential growth and a 6.8% year-on-year growth.
- Order book mix for the quarter is disproportionately high from the U.K./Europe business, which involves significant long-term contracts.
- In North America, shorter-term contracts are more common recently, with clients preferring 6-month to 1-year deals instead of 3- to 5-year deals, causing order book growth to be muted but possibly improving revenue conversion ratios.
- The overall order book growth rate has slowed down to about 7% year-on-year, partly due to delayed decision-making and clients evaluating AI impacts on budgets.
2 more points from Mastek Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Mastek Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹938 Cr, net profit ₹106 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mastek's management said in earlier quarters
Others in IT - Software this season
- Softtech Enginee (Q2 FY26)
Standalone: Rs 25.71 Cr (up from Rs 22.93 Cr in Q2 FY 2024-25) — approx. Key investor presentation takeaways from Softtech Engineers Ltd's Q2 FY26 investor pres
- Systango Tech (Q2 FY26)
Year-on-Year (YoY) revenue growth for H1-FY26 is 58.0% compared to H1-FY25 revenue of INR 288 million. Key investor presentation takeaways from Systango Technol
- 3i Infotech Ltd (Q2 FY26)
Q2 FY26 consolidated revenue from operations: ₹174.9 crore, a 2.5% increase quarter-on-quarter (QoQ) but a 2% decrease year-on-year (YoY) from ₹177.6 crore in…
- C.E. Info Systems Ltd (Q2 FY26)
IoT-led business growth is robust, with a 50% revenue increase from INR 54 crores to INR 74.5 crores year-on-year. Key concall takeaways from C.E. Info Systems…
Arthneeti Pro · Annual
Mastek Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mastek Ltd Q2 FY26 results?
Mastek expects significant overall services growth driven by AI investments. - Short-term uncertainties and decision-making delays exist, but strong optimism about AI-led technology disruption remains. - North America is projected to see growth, especially in healthcare and life sciences, with improving order book to revenue conversion. - U.K. Mastek anticipates steady and positive growth in H2 FY26 despite macro and global uncertainties (Page 14).
What is Mastek Ltd share price analysis?
Mastek Ltd currently shows a neutral. The stock trades at a P/E of 12.9 with a market cap of ₹5,667 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mastek Ltd planning capital expenditure?
Mastek is heavily investing in AI, focusing on both AI-for-technology (improving productivity and efficiency in technology services) and AI-for-business (delivering AI-led business transformation solutions).
Keep Mastek Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.